Aging Is Becoming a Drug Target. The Question Is Whether It’s a Disease
The Race to Turn Back the Clock

The ambitions become even more striking in the XPRIZE Healthspan competition, which challenges teams to restore muscle strength, cognitive function, and immune performance in adults aged 50 to 90. The target is an improvement equivalent to at least 10 years of biological function, with an aspirational goal of 20 years, achieved within a treatment period of one year or less.
One participating team is pursuing engineered super exosomes designed to target senescent cells. These cells have stopped dividing but remain metabolically active, releasing inflammatory signals that can damage surrounding tissue and contribute to age-related dysfunction. By targeting cellular processes associated with aging, the approach aims to restore function across multiple systems simultaneously.
The team estimates that its preclinical results correspond to more than 15 healthy human years. Such projections illustrate the scale of the competition’s ambitions: researchers are attempting to demonstrate measurable rejuvenation, rather than simply slowing the rate of decline.
That distinction could determine the future of longevity medicine. A treatment that delays deterioration may offer incremental benefits. One that restores lost function could fundamentally change what clinicians and patients expect from later life.